2023 annual financial data
ProQR Therapeutics 2023 Operating margin
Direct answer
Operating margin was -489.09%.
Operating income was -31,859,000 EUR and net income was -28,119,000 EUR.
Operating cash flow was 21,548,000 EUR.
Get free ProQR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 6,514,000 EUR
- Operating income
- -31,859,000 EUR
- Net income
- -28,119,000 EUR
- Operating cash flow
- 21,548,000 EUR